New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1] - PRNewswire

Submitted by Anonymous (not verified) on Tue, 05/21/2019 - 11:30

New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]  PRNewswireNEW ORLEANS, May 21, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the ...